Therapeutic effects of HESA.A in acute organophosphorous pesticide poisoning

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138811062083N2

Enrollment

Registered

2014-02-18

Start date

2014-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute organophosphorous pesticide poisoning. Toxic effect of pesticides - Organophosphate and carbamate insecticides

Interventions

Intervention 1: Control group (treated by Atropine and Normal Saline). Intervention 2: treated by Atropine and HESA-A 50mg/kg. Intervention 3: treated by Atropine and HESA-A 20mg/kg.

Treatment - Drugs

Control group (treated by Atropine and Normal Saline)

treated by Atropine and HESA-A 50mg/kg

treated by Atropine and HESA-A 20mg/kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with moderate to severe organophosphate poisoning according to the following protocol: Moderate poisoning: miosis, decreased level of consciousness, nausea and vomiting, hypersalivation, abdominal cramp, muscular fasciculation, dysarthria, ataxia, acetylcholinesterase level: 10%-20% of the normal level Severe poisoning: coma, pinpoint pupils (which are nonreactive to direct light stimuli), diarrhea, respiratory compromise, pulmonary edema, flaccid paralysis, muscular fasciculation, seizure, heart block, hyperglycemia, acetylcholinesterase level: less than 10% of the normal level Exclusion criteria: 1. Previous history of cardiovascular, neurologic, respiratory, hepatic or renal dysfunction 2. Diabetes Mellitus 3. Patients taking digitalis 4. Those under CNS depressants 5. Those under neuromuscular receptor blockers 6. Those who are treated with pralidoxime

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Increased level of RBC cholinesterase activity. Timepoint: Before intervention and then on a daily basis. Method of measurement: Blood test.;Decreasing the need for ICU admission. Timepoint: After intervention. Method of measurement: adding up the days of ICU admission in all groups.;Decreasing the need for mechanical ventilation. Timepoint: Before intervention and then, on a daily basis. Method of measurement: Duration necessary for mechanical ventilation.;Decreasing the need for treatment with atropine. Timepoint: Before intervention and then on a daily basis. Method of measurement: recording and calculating the total amount of atropine taken.;Decreasing the need for treatment with benzodiazepine. Timepoint: Before intervention and then on a daily basis. Method of measurement: recording and calculating the total amount of benzodiazepine taken.	—

Measure

Time frame

Increased level of RBC cholinesterase activity. Timepoint: Before intervention and then on a daily basis. Method of measurement: Blood test.;Decreasing the need for ICU admission. Timepoint: After intervention. Method of measurement: adding up the days of ICU admission in all groups.;Decreasing the need for mechanical ventilation. Timepoint: Before intervention and then, on a daily basis. Method of measurement: Duration necessary for mechanical ventilation.;Decreasing the need for treatment with atropine. Timepoint: Before intervention and then on a daily basis. Method of measurement: recording and calculating the total amount of atropine taken.;Decreasing the need for treatment with benzodiazepine. Timepoint: Before intervention and then on a daily basis. Method of measurement: recording and calculating the total amount of benzodiazepine taken.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSyed Reza Mousavi

Medical Toxicology Research Center

mousavir@mums.ac.ir+98 51 1859 8973

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026